Jefferies Maintains a 'Buy' on NxStage Medical (NXTM); Adjusting Outlook

Jefferies maintains a 'Buy' on NxStage Medical (NASDAQ: NXTM) price target of $21.00.

Analyst, Raj Denhoy, said, "Following last week’s 2Q earnings, we’ve revisited our NXTM model and made some minor tweaks, most notably a tempering of our sequential US home hemodialysis revenue growth assumptions for the back half offset somewhat by slightly higher sales projections for international HHD. Overall, there are no material changes to our forecasts, nor our long-term investment thesis."

Sees current quarter EPS at (0.07), FY at (0.31) and next year at (0.09)

For an analyst ratings summary and ratings history on NxStage Medical click here. For more ratings news on NxStage Medical click here.

Shares of NxStage Medical closed at $13.10 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15